Proteocyte Announces Dr. Paras B. Patel as new U.S. Lab Director

Toronto, ON; April 23, 2024 – Proteocyte AI is pleased to announce the opening of their U.S. lab operations in Dallas, Texas, and the appointment of Dr. Paras B. Patel as their U.S. Lab Director.

Dr. Patel’s breadth of training and experience has shaped his approach to diagnosis and management of oral diseases and directly aligns with Proteocyte’s focus on solutions for early prognosis and management of oral cancer.

In addition to developing and founding the Center for Oral Pathology, he has recently helped establish the division of Oral and Maxillofacial Pathology at ProPath, where he currently serves as director today.

“I am excited to collaborate with Proteocyte AI in advancing the development of more accurate prognostic models for transformation” states Dr. Patel. “This signifies the early stages of a paradigm shift from an era of subjective evaluation to objective quantifiable measures that can stratify risks for the development of oral cancer. The future looks promising for our patients.”

Dr. Patel’s training, experience and extensive network of oral pathologists, oral medicine specialists, and oral surgeons will be valuable to Proteocyte’s growth, as the company continues to build out a highly experienced and knowledgeable team to support its expansion into the U.S.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.